Abbvie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
艾伯維公司與正大天晴宣佈合作開發一種新型三特異性抗體候選藥物用於多發性骨髓瘤
Abbvie and Simcere Zaiming Announce Partnership to Develop a Novel Trispecific Antibody Candidate in Multiple Myeloma
艾伯維公司與正大天晴宣佈合作開發一種新型三特異性抗體候選藥物用於多發性骨髓瘤
譯文內容由第三人軟體翻譯。
評論(0)
請選擇舉報原因